EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieKlinische Studie (Phase IV)VergleichsstudieOpen Access · CC BY 4.0

Comparison of treatment routine using aflibercept: Strict vs. relaxed retreatment regimen ( TOLERANT study)—A non‐inferiority, randomized controlled trial

Damian Jaggi iD, Lieselotte E Berger, Sandrine Zweifel, Matthias D Becker, Stephan Michels, Odile Stalder, Joel-Benjamin Lincke, Oussama Habra, Sebastian Wolf, Martin S Zinkernagel

Acta Ophthalmologica · 2025

DOI: 10.1111/aos.17514 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Acta Ophthalmologica, 2025. Verfasst von Damian Jaggi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Recombinant Fusion Proteins, Receptors, Vascular Endothelial Growth Factor, Visual Acuity, Wet Macular Degeneration. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This trial evaluated the noninferiority of a relaxed compared to a strict treat‐and‐extend treatment strategy in patients with neovascular Age‐related macular degeneration (AMD).

Methods

Multicenter, randomized, controlled, phase IV, non‐inferiority clinical trial. Patients with treatment‐naïve nAMD were randomized 1:1 to a relaxed or strict treat‐and‐extend treatment regimen. Aflibercept 2 mg/0.05 mL was used. In the relaxed regimen, up to 100 μm subfoveal subretinal fluid was tolerated, vs. no tolerance of any fluid in the strict regimen. The primary outcome was the change in best corrected visual acuity (BCVA; ETDRS letters) from baseline to the end of the study at week 104 and its difference between the two treatment arms, with a 5‐letter non‐inferiority margin.

Results

We randomized 150 patients. The full analysis showed non‐inferiority of the relaxed treatment, with a mean difference of −0.12 letters (95%‐CI: −3.45 to infinity, H0; mean. diff. ≤ 5 letters: p = 0.008), and a visual acuity gain of 7.3 (4.82; 9.78) vs. 7.01 (3.67; 10.36) letters in the strict vs. relaxed regimen, respectively. Many patients deviated from the protocol due to Covid‐19. Per‐protocol analysis showed a mean difference of −1.78 letters (95%‐CI: −6.61 to infinity, H0; mean. diff. ≤ 5 letters: p = 0.136). Fewer injections were needed in the relaxed regimen, with a mean difference of −2.34 (95%‐CI: −4.11 to −0.56, p = 0.01).

Conclusion

Tolerating up to 100 μm subfoveal subretinal fluid achieves good visual outcomes in our 24‐month follow‐up period, in patients treated with aflibercept for nAMD, with significantly fewer injections needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Recombinant Fusion ProteinsReceptors, Vascular Endothelial Growth FactorVisual AcuityWet Macular DegenerationHumansIntravitreal InjectionsFemaleMaleAgedTomography, Optical CoherenceTreatment OutcomeAngiogenesis InhibitorsRetreatmentFollow-Up StudiesFluorescein AngiographyVascular Endothelial Growth Factor AAged, 80 and overFundus OculiMiddle Aged

Stichwörter der Autor:innen

AMDafliberceptanti‐VEGFsubretinal fluidtolerancetreat‐and‐extend

Substanzen

afliberceptRecombinant Fusion ProteinsReceptors, Vascular Endothelial Growth FactorAngiogenesis InhibitorsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Department of BioMedical Research, University of Bern, Bern, Switzerland.
  • Department of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Spross Research Institute, Department of Ophthalmology, Zürich City Hospital, Zürich, Switzerland.
  • Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany.
  • Augenklinik Zürich West, Switzerland.

ORCID-Profile: Damian Jaggi

Förderung

  • Bayer

Zitieren

APA

Jaggi, D., Berger, L. E., Zweifel, S., Becker, M. D., Michels, S., Stalder, O., Lincke, J. B., Habra, O., Wolf, S., & Zinkernagel, M. S. (2025). Comparison of treatment routine using aflibercept: Strict vs. relaxed retreatment regimen ( TOLERANT study)—A non‐inferiority, randomized controlled trial. Acta Ophthalmologica. https://doi.org/10.1111/aos.17514

Vancouver

Jaggi D, Berger LE, Zweifel S, Becker MD, Michels S, Stalder O, et al. Comparison of treatment routine using aflibercept: Strict vs. relaxed retreatment regimen ( TOLERANT study)—A non‐inferiority, randomized controlled trial. Acta Ophthalmologica. 2025. doi:10.1111/aos.17514

BibTeX
@article{Jaggi2025,
  author = {Jaggi, Damian and Berger, Lieselotte E and Zweifel, Sandrine and Becker, Matthias D and Michels, Stephan and Stalder, Odile and Lincke, Joel-Benjamin and Habra, Oussama and Wolf, Sebastian and Zinkernagel, Martin S},
  title = {Comparison of treatment routine using aflibercept: Strict vs. relaxed retreatment regimen ( TOLERANT study)—A non‐inferiority, randomized controlled trial},
  journal = {Acta Ophthalmologica},
  year = {2025},
  doi = {10.1111/aos.17514}
}
Kostenlos starten →